BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

270 related articles for article (PubMed ID: 34973063)

  • 1. Impact on NK cell functions of acute versus chronic exposure to extracellular vesicle-associated MICA: Dual role in cancer immunosurveillance.
    Vulpis E; Loconte L; Peri A; Molfetta R; Caracciolo G; Masuelli L; Tomaipitinca L; Peruzzi G; Petillo S; Petrucci MT; Fazio F; Simonelli L; Fionda C; Soriani A; Cerboni C; Cippitelli M; Paolini R; Bernardini G; Palmieri G; Santoni A; Zingoni A
    J Extracell Vesicles; 2022 Jan; 11(1):e12176. PubMed ID: 34973063
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cross-Dressing of Multiple Myeloma Cells Mediated by Extracellular Vesicles Conveying MIC and ULBP Ligands Promotes NK Cell Killing.
    Vulpis E; Loconte L; Cassone C; Antonangeli F; Caracciolo G; Masuelli L; Fazio F; Petrucci MT; Fionda C; Soriani A; Cerboni C; Cippitelli M; Santoni A; Zingoni A
    Int J Mol Sci; 2023 May; 24(11):. PubMed ID: 37298418
    [TBL] [Abstract][Full Text] [Related]  

  • 3. c-Cbl regulates MICA- but not ULBP2-induced NKG2D down-modulation in human NK cells.
    Molfetta R; Quatrini L; Capuano C; Gasparrini F; Zitti B; Zingoni A; Galandrini R; Santoni A; Paolini R
    Eur J Immunol; 2014 Sep; 44(9):2761-70. PubMed ID: 24846123
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Interaction of monocytes with NK cells upon Toll-like receptor-induced expression of the NKG2D ligand MICA.
    Kloss M; Decker P; Baltz KM; Baessler T; Jung G; Rammensee HG; Steinle A; Krusch M; Salih HR
    J Immunol; 2008 Nov; 181(10):6711-9. PubMed ID: 18981088
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Novel role for STAT3 in transcriptional regulation of NK immune cell targeting receptor MICA on cancer cells.
    Bedel R; Thiery-Vuillemin A; Grandclement C; Balland J; Remy-Martin JP; Kantelip B; Pallandre JR; Pivot X; Ferrand C; Tiberghien P; Borg C
    Cancer Res; 2011 Mar; 71(5):1615-26. PubMed ID: 21257710
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Immunomodulatory effect of NEDD8-activating enzyme inhibition in Multiple Myeloma: upregulation of NKG2D ligands and sensitization to Natural Killer cell recognition.
    Petillo S; Capuano C; Molfetta R; Fionda C; Mekhloufi A; Pighi C; Antonangeli F; Zingoni A; Soriani A; Petrucci MT; Galandrini R; Paolini R; Santoni A; Cippitelli M
    Cell Death Dis; 2021 Sep; 12(9):836. PubMed ID: 34482362
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The activating NKG2D ligand MHC class I-related chain A transfers from target cells to NK cells in a manner that allows functional consequences.
    McCann FE; Eissmann P; Onfelt B; Leung R; Davis DM
    J Immunol; 2007 Mar; 178(6):3418-26. PubMed ID: 17339436
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Soluble ligands for the NKG2D receptor are released during HIV-1 infection and impair NKG2D expression and cytotoxicity of NK cells.
    Matusali G; Tchidjou HK; Pontrelli G; Bernardi S; D'Ettorre G; Vullo V; Buonomini AR; Andreoni M; Santoni A; Cerboni C; Doria M
    FASEB J; 2013 Jun; 27(6):2440-50. PubMed ID: 23395909
    [TBL] [Abstract][Full Text] [Related]  

  • 9. MICA-129 Dimorphism and Soluble MICA Are Associated With the Progression of Multiple Myeloma.
    Zingoni A; Vulpis E; Cecere F; Amendola MG; Fuerst D; Saribekyan T; Achour A; Sandalova T; Nardone I; Peri A; Soriani A; Fionda C; Mariggiò E; Petrucci MT; Ricciardi MR; Mytilineos J; Cippitelli M; Cerboni C; Santoni A
    Front Immunol; 2018; 9():926. PubMed ID: 29765374
    [TBL] [Abstract][Full Text] [Related]  

  • 10. HLA class I, NKG2D, and natural cytotoxicity receptors regulate multiple myeloma cell recognition by natural killer cells.
    Carbone E; Neri P; Mesuraca M; Fulciniti MT; Otsuki T; Pende D; Groh V; Spies T; Pollio G; Cosman D; Catalano L; Tassone P; Rotoli B; Venuta S
    Blood; 2005 Jan; 105(1):251-8. PubMed ID: 15328155
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Major histocompatibility complex class I-related chain A and UL16-binding protein expression on tumor cell lines of different histotypes: analysis of tumor susceptibility to NKG2D-dependent natural killer cell cytotoxicity.
    Pende D; Rivera P; Marcenaro S; Chang CC; Biassoni R; Conte R; Kubin M; Cosman D; Ferrone S; Moretta L; Moretta A
    Cancer Res; 2002 Nov; 62(21):6178-86. PubMed ID: 12414645
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Inhibition of bromodomain and extra-terminal (BET) proteins increases NKG2D ligand MICA expression and sensitivity to NK cell-mediated cytotoxicity in multiple myeloma cells: role of cMYC-IRF4-miR-125b interplay.
    Abruzzese MP; Bilotta MT; Fionda C; Zingoni A; Soriani A; Vulpis E; Borrelli C; Zitti B; Petrucci MT; Ricciardi MR; Molfetta R; Paolini R; Santoni A; Cippitelli M
    J Hematol Oncol; 2016 Dec; 9(1):134. PubMed ID: 27903272
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Generation of soluble NKG2D ligands: proteolytic cleavage, exosome secretion and functional implications.
    Chitadze G; Bhat J; Lettau M; Janssen O; Kabelitz D
    Scand J Immunol; 2013 Aug; 78(2):120-9. PubMed ID: 23679194
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cancer exosomes and NKG2D receptor-ligand interactions: impairing NKG2D-mediated cytotoxicity and anti-tumour immune surveillance.
    Mincheva-Nilsson L; Baranov V
    Semin Cancer Biol; 2014 Oct; 28():24-30. PubMed ID: 24602822
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Shedding of endogenous MHC class I-related chain molecules A and B from different human tumor entities: heterogeneous involvement of the "a disintegrin and metalloproteases" 10 and 17.
    Chitadze G; Lettau M; Bhat J; Wesch D; Steinle A; Fürst D; Mytilineos J; Kalthoff H; Janssen O; Oberg HH; Kabelitz D
    Int J Cancer; 2013 Oct; 133(7):1557-66. PubMed ID: 23526433
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Valproic acid upregulates NKG2D ligand expression through an ERK-dependent mechanism and potentially enhances NK cell-mediated lysis of myeloma.
    Wu X; Tao Y; Hou J; Meng X; Shi J
    Neoplasia; 2012 Dec; 14(12):1178-89. PubMed ID: 23308050
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Functional Characterisation and Analysis of the Soluble NKG2D Ligand Repertoire Detected in Umbilical Cord Blood Plasma.
    Cox ST; Danby R; Hernandez D; Laza-Briviesca R; Pearson H; Madrigal JA; Saudemont A
    Front Immunol; 2018; 9():1282. PubMed ID: 29963042
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cervical cancer cell lines expressing NKG2D-ligands are able to down-modulate the NKG2D receptor on NKL cells with functional implications.
    Jimenez-Perez MI; Jave-Suarez LF; Ortiz-Lazareno PC; Bravo-Cuellar A; Gonzalez-Ramella O; Aguilar-Lemarroy A; Hernandez-Flores G; Pereira-Suarez AL; Daneri-Navarro A; del Toro-Arreola S
    BMC Immunol; 2012 Feb; 13():7. PubMed ID: 22316211
    [TBL] [Abstract][Full Text] [Related]  

  • 19. MICA immune complex formed with alpha 3 domain-specific antibody activates human NK cells in a Fc-dependent manner.
    Du C; Bevers J; Cook R; Lombana TN; Rajasekaran K; Matsumoto M; Spiess C; Kim JM; Ye Z
    J Immunother Cancer; 2019 Aug; 7(1):207. PubMed ID: 31387641
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Functional expression and release of ligands for the activating immunoreceptor NKG2D in leukemia.
    Salih HR; Antropius H; Gieseke F; Lutz SZ; Kanz L; Rammensee HG; Steinle A
    Blood; 2003 Aug; 102(4):1389-96. PubMed ID: 12714493
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.